MiNK Therapeutics to Present iNKT Cell Therapy in Gastric Cancer at ASCO GI Annual Meeting [Yahoo! Finance]
MiNK Therapeutics to Present iNKT Cell Therapy in Gastric Cancer at ASCO GI Annual Meeting
FairJourney Biologics Appoints Dr. Marc van Dijk as Chief Scientific Officer of Antibody Discovery and Engineering [Yahoo! Finance]
MiNK Therapeutics, Inc. (NASDAQ: INKT) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $9.00 price target on the stock.
MiNK Therapeutics, Inc. (NASDAQ: INKT) had its price target lowered by analysts at Robert W. Baird from $8.00 to $4.00. They now have an "outperform" rating on the stock.